Promising combo tackles FLT3 leukemia in early trial
Disease control
Completed
This early-phase study tested whether adding two targeted drugs, gemtuzumab ozogamicin and midostaurin, to standard chemotherapy is safe for people with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) that has a FLT3 mutation. The trial enrolled 21 adults and a…
Phase: PHASE1 • Sponsor: Uma Borate • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC